The proliferative effects of physiological concentrations of T4 and estradiol on ERα in human breast cancer cells are comparable and are similarly reduced by pharmacologic inhibition of mitogen-activated protein kinase (MAPK) activity (4). The gene discussed is ESR1; the disease is breast cancer.